Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronaviruses

Antibody repertoires against hCoVs and cross-reactivities

Antibody binding against SARS-CoV-2 is typically assessed by ELISAs against full length proteins/domains (20, 21) or by resolving crystal structures (14, 22). Pinpointing protein segments recognized by cross-reactive antibodies of all hCoVS requires higher resolution methods. Phage immunoprecipitation sequencing (PhIP-Seq) relies on the display of synthetic oligo libraries on T7 phages (11, 12). Thereby displayed antigens can be rationally selected allowing to probe for hundred thousands of antigens in parallel. After mixing of the phage library with serum antibodies, unbound phages are washed away after immunoprecipitation and enriched phages are detected by next generation sequencing (Fig. 1a).

• Download figure
• Open in new tab

Fig. 1:

A phage displayed antigen library (a) of human Coronaviruses’ peptide antigens (b) applied to serum samples of unexposed individuals and recovered COVID-19 patients (c) detects a high serum prevalence of seasonal hCoVs, interindividual variability of antibody repertoires against SARS-CoV-2, and cross-reactive antibody responses from SARS-CoV-2 infection (d-k).

The numbers of proteins per strain in panel b include polyproteins being split into 14 separate proteins. d-k, All bound antigens of the hCoV library are shown in panel d, the following panels depict binding against peptides of each hCoV strain separately. The illustration of the SARS-CoV-2 virion is reproduced from CDC PHIL #23312 released as public domain (CDC/ Alissa Eckert, MSMI; Dan Higgins, MAMS), the phylogenetic tree is reproduced form Wu et al. (1) [open access].

We have generated a PhIP-Seq library covering all open reading frames of hCoVs as 64 amino acid (aa) sections with 20 aa overlaps between adjacent peptides (Fig. 1b). The library also includes positive controls which confirmed detection of antibody responses against viruses previously reported to elicit population wide immunity (12) and negative controls, that did not show substantial binding (Table S 1).

We tested IgG antibody binding against this hCoV library with 32 serum samples of individuals unexposed to SARS-CoV-2, that had been collected in 2013/2014 (23) before the COVID-19 outbreak (Fig. 1c). These antibody repertoires were compared to 32 samples of recovered COVID-19 patients obtained in April and May 2020. In total we have assayed for nearly 100,000 antibody-peptide interactions (1,539 hCoV peptides in each of the 64 individuals). Employing strict Bonferroni correction, 240/1,539 peptides were enriched in at least one individual, with an average of 9 hCoV peptides significantly bound per unexposed individual and 19 hCoV peptides in recovered COVID-19 patients. Most analyses were based on antibody responses against 57 hCoV peptides from 32 different hCoV proteins, shared by more than five individuals of either group and seven peptides showing significantly different abundances between the groups (Table S 2).

Unexposed individuals showed abundant antibody responses against all seasonal hCoVs: Binding against peptides of hCoV-NL63 was detected in 75% of unexposed individuals, against hCoV-HKU1 in 66%, against hCoV-229E in 63%, and against hCoV-OC43 in 38% (Fig. 1h-k, Table S 2). The same peptides were bound at similar frequencies in recovered COVID-19 patients and originated mostly from S-or N-proteins (Table S 2). Binding of any peptide from seasonal hCoV S-or N-proteins was detectable in 78% of unexposed individuals for hCoV-NL63, 75% for hCoV-HKU1, and 63% for hCoV-229E and hCoV-OC43 with these epitope resolved results being in agreement with previous studies on the seroprevalence of seasonal hCoVs using ELISAs (24).

Recovered COVID-19 patients’ sera showed, as expected, an overrepresentation of several peptides of SARS-CoV-2 that completely lacked binding in unexposed individuals, with five peptides passing FDR (false discovery rate) correction for being significantly different between the two groups of individuals (Table S 2). While nearly all COVID-19 patients showed binding against at least one peptide in S-or N-proteins and some peptides being bound in up to 72% of recovered patients (Fig. 1e), no convergence of antibody responses against the same peptide were detected in all individuals. This finding differs from near universal recognition of some viral epitopes previously observed for other human viruses (12) and replicated with controls in this study (S 1), suggesting that the antibody response against SARS-CoV-2 can exhibit substantial inter-individual variability.

COVID-19 serum samples showed also common binding against SARS-CoV-1, indicating detection of cross-reactivity of antibodies targeting SARS-CoV-2 (Fig. 1f) (14, 15), most notably one SARS-CoV-1 spike peptide had significantly enriched binding in up to 84% of COVID-19 recovered individuals compared to 6% of unexposed individuals (Table S 2). A non-structural protein (NSP3) of SARS-CoV-1 was even bound in 13% of unexposed individuals and 22% of recovered, possibly owing to higher conservation of such NSPs underlying less selective pressure than S- and N-proteins mostly responsible for infectivity and targeted by neutralizing immune responses. A few other peptides were differentially enriched between the two groups, but did not pass FDR correction for significance of this difference, including a peptide of the MERS-CoV S-protein bound in 28% of COVID-19 sera and 3% (1/32) of unexposed individuals (Fig. 1g).

Strikingly, cross-reactive responses from SARS-CoV-2 also extended to the seasonal hCoVs-OC43 (Fig. 1h). One hCoV-OC43 spike peptide was bound in 50% of COVID-19 sera and 3% (1/32) of unexposed individuals, passing FDR correction for being differentially enriched between the two groups (Table S 2). Another two peptides of hCoV-OC43 spike were not bound in unexposed individuals at all, but bound in up to 28% of COVID-19 patients, neither passing FDR correction (Table S 2). Differential binding of hCoV-HKU1 was less pronounced with one peptide occurring in 19% of COVID 19 patients and 3% (1/32) of unexposed individuals (Fig. 1i) not passing FDR correction (Table S 2). We did not detect cross-reactivities against peptides from the alpha coronaviruses (hCoV-NL63 and CoV-229E), with COVID-19 patients and healthy individuals’ sera reacting at similar rates (Fig. 1j,k). Peptides eliciting cross-reactive antibody responses between SARS-CoV-2, SARS-CoV-1, and seasonal hCoVs typically originated from similar regions of S-(Fig. 2a) and N-(Fig. 2b) proteins. This data indicates that epitopes in the SARS-CoV-2 spike S2 region are frequently bound in COVID-19 patients and a target for cross-reactivity. Many recombinant SARS-CoV-2 vaccines in development focus either on the full-length spike or the RBD alone (25). The observed S2 reactivity could lead to differences between these designs, with responses against full-length S-protein vaccines potentially benefiting from cross-reactivities against seasonal hCoVs, which may not occur for RBD only vaccines.

• Download figure
• Open in new tab

Fig. 2:

Cross-reactive and selective antibody binding of SARS-CoV-2 peptides and other hCoVs clusters in similar regions of the spike (a) and nucleocapsid (b) protein.

Alignments of S-and N-proteins of all hCoVs, the dark line next to the strain identifier represents the protein sequence indicating gaps in the consensus alignment. Peptides bound in more than five unexposed (‘U’) individuals or recovered COVID-19 patients (‘C’) are shown as arrows above the corresponding protein sequence. The abundance of binding in ‘U’ and ‘C’ is indicated as percentages written next to the peptides. Grey arrows indicate similar recognition in unexposed individuals and COVID-19 patients, blue arrows indicate more than two-fold overrepresented binding in COVID-19 patients. Peptides marked with an asterisk appear at significantly different abundances (passing FDR correction) between unexposed individuals and recovered COVID-19 patients, by scoring the difference between the two distributions of the log fold changes (number of reads of bound peptides vs. baseline sequencing of phages not undergoing IPs) of the two groups (Table S 2). The domain structure on top of each panel is based on SARS-CoV-2 S-(32)/N-(33) proteins, positions in other hCoVs shift along the alignment. Due to the different lengths of S-and N-proteins, the two panels are not drawn at the same scale.

When looking at the principal components of an analysis (PCA, Fig. 3a) performed on the log fold change (number of reads of bound peptides vs. baseline sequencing of phages not undergoing immunoprecipitation) of significantly enriched oligos, unexposed individuals clustered together while recovered COVID-19 patients’ samples showed a greater spread. This illustrates the interindividual variability in hCoV antibody responses elicited by SARS-CoV-2.

• Download figure
• Open in new tab

Fig. 3:

Principal component analysis (PCA) separates between hCoV antibody responses of unexposed individuals and recovered COVID-19 patients (a) and a machine learning predictor accurately identifies infected individuals (b,c).

Gradient boosting decision trees (XGBoost classifier (34)) with leave-one-out cross-validation were used for these predictions on hCoV peptides bound in >4 (5%) individuals. Area under the curve (b) and precision-recall curve (c) of predicting COVID-19 status from antibody responses against hCoV peptides (abbreviations: PPV - positive predictive value).

Overall, this data indicates that substantial cross-reactivity between hCoVs observed for T cells (7, 8) also extends to antibody responses against seasonal hCoVs. We show that infection with SARS-CoV-2 mounts cross reactive antibodies against hCoV-OC43 antigens. The reverse direction of preexisting antibody responses targeting seasonal hCoVs recognizing SARS-CoV-2 is more difficult to assess. We observed binding of two SARS-CoV-2 epitopes in a few unexposed individuals (peptides from NSP2 in 19% and N protein in 6% (2/32), Table S 2). The abundance of responses against NSP2 did not change in recovered COVID-19 patients, but binding of the N-protein antigen increased to 66% of recovered patients. We also detected additional SARS-CoV-2 peptides bound in single healthy individuals (including a spike peptide, Fig. 2a) similar to a population-wide abundance of 3% (1/32) in unexposed individuals reported by a recent study comparing four antibody tests for the SARS-CoV-2 S/N proteins (26). hCoV peptides bound at higher abundance in unexposed individuals than recovered COVID-19 patients, would suggest a protective nature. As we did not detect any such peptides our data does not support such a simple protective mechanism.

Assessing the protective nature of these population wide preexisting responses would require comparing samples of the same individuals before and after contracting COVID-19 and information on the course (severity) of the disease. The COVID-19 cohort of this study consisted of patients who had experienced mild symptoms, and had not required hospitalization (testing positive in PCR and serological tests). Employing our antigen library to compare antibody profiles against seasonal hCoVs between mild and severe COVID-19 cases could also inform on protective effects of cross-reactivity, as demonstrated for other aspects of the anti-SARS-CoV-2 immune response (27) and antibody binding of SARS-CoV-2 proteins (20). If severe patients exhibited fewer antibody responses against antigens of seasonal hCoVs, could point towards their protective nature. Moreover, possible detrimental effects of cross-reactive antibody responses originating from seasonal hCoVs leading to antibody-dependent enhancement (28) could be assessed with our hCoV antigen library.

hCov library based high throughput diagnostics

Testing for multiple hCoV antigens at high resolution in parallel could yield higher specificity than conventional tests based on single proteins of SARS-CoV-2 by improving discrimination from seasonal hCoVs. Most current SARS-CoV-2 serological tests rely on detection of entire S-/RBD or N-proteins, reporting an aggregate of binding against all epitopes within (21, 29). Interpreting the epitope-resolved antibody binding data reported by our assay extends beyond conventional serological tests, as binding against various epitopes of all hCoV needs to be weighed. We used machine learning to build a predictor that highly accurately separated COVID-19 patients from healthy controls based on antibody signatures (AUC=0.96, Fig. 3b). Depending on the intended application and cutoffs employed (Fig. 3c), this assay can display 100% specificity at 72% sensitivity (reporting virtually no false-positives) or 94% specificity at 91% sensitivity. Hence, in addition to informing on cross-reactivity between hCoVs, our antigen library could also represent a tool for SARS-CoV-2 diagnostics.

From a technical perspective, our study shares general limitations of PhIP-Seq, most notable length constraints of presented peptides (64 aa in this study) by underlying oligo synthesis and lack of eukaryotic post translational modifications such as glycosylation. Opposed to neutralization assays carried out with live viruses and cell cultures (29), our data does not inform on the neutralizing capacity of the observed binding events. While linear epitopes should be adequately covered, discontinuous, conformational epitopes relying on the correct folding of domains could be missed. We did not frequently detect binding to peptides of the RBD (with one adjacent peptide bound in 25% of COVID-19 and 0% of unexposed individuals’ sera, Fig. 2a), although other work and diagnostic tests relying on the full length RBD had reported common antibody responses in COVID-19 patients (14,16, 17, 21). This discrepancy may be due antibody responses against conformational epitopes in the RBD and/or a lack of S protein glycans (30) in the phage displayed peptides.

While current oligo lengths employed in PhIP-Seq may underestimate conformational epitopes, it provides a unique layer of information unobtainable from working with full length antigens or isolated domains: Given the high resolution of the peptide approach, we pinpoint the exact bound regions revealing crucial targets of cross-reactivities. Our hCoV antigen library can be leveraged to study extended cohorts of patients with mild/severe disease courses or samples collected pre/post COVID-19 infection, and could thereby inform on the potential protective nature of preexisting antibody responses against seasonal hCoVs. In addition, our approach can be extended to other antibody isotypes such as IgA, the primary mucosal antibody. Given the low cost of processing phage displayed libraries in parallel (31), high accuracy (Fig. 3b,c), and its excellent amenability for robot automation (12, 31), serological testing based on this hCoV library could be a broadly applicable tool to assess preexisting immunity at population-scale (with implications towards protection and herd immunity of SARS-CoV-2) as well as stratifying vaccine trial costs effectively.